866-997-4948(US-Canada Toll Free)

Cisplatin (Non Small Cell Lung Cancer) Analysis and forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Non Small Cell Lung Cancer

No. of Pages : 32 Pages

 

GlobalDatas pharmaceuticals report, Cisplatin (Non Small Cell Lung Cancer) - Analysis and Estimates from 2002 to 2020 provides cisplatin sales estimates for the US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Non Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData\'s team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of cisplatin including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of cisplatin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2002-2020 for cisplatin in the US, EU5 and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 6
2.3.4 Other Environmental Agents 7
2.4 GlobalData Pipeline Report Guidance 8


3 NSCLC Disease: Market Characterization 9
3.1 NSCLC Disease Market 9
3.2 NSCLC Disease Market Forecasts and CAGR 9
3.3 Drivers for the NSCLC Disease Market 9
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 10
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 11
3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 11
3.3.5 Promising Pipeline Drugs 11


4 TNM Classification of NSCLC 12


5 Cisplatin 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Approval History of Cisplatin 16
5.5 Factors Affecting Sales of Cisplatin 16
5.5.1 Dominance of Platinum Based Drug Cisplatin 16
5.5.2 Multidrug Regimens 16
5.5.3 Administered for both Operable and Inoperable Patients 16
5.6 Drug Risk Benefit Score 16
5.6.1 Efficacy 17
5.6.2 Safety 17
5.6.3 Compliance 17
5.6.4 Dosing Convenience 17
5.7 Intensity of Competition 17
5.8 Sales forecast 18
5.8.1 Target patient Pool of Cisplatin 18
5.8.2 Dosing 18
5.8.3 Market Penetration 18
5.8.4 Annual Cost of Therapy 19
5.8.5 Sales Projections of Cisplatin 19


6 NSCLC Market: Appendix 28
6.1 Market Definitions 28
6.2 Abbreviations 28
6.3 Research Methodology 28
6.3.1 Coverage 29
6.3.2 Secondary Research 29
6.3.3 Forecasting 29
6.3.4 Number of Patients Approved to take the Drug 29
6.3.5 Net Penetration of Drug 30
6.3.6 Net Annual Dosing 31
6.3.7 Annual Cost of Therapy 31
6.3.8 Primary Research 31
6.3.9 Expert Panels 31
6.4 Contact Us 32
6.5 Disclaimer 32
6.6 Sources 32

List of Table


Table 1: NSCLC, Incidences and Mortality, 20082030 5
Table 2: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Table 3: Drug Risk Benefit Score of Cisplatin plus Navelbine 17
Table 4: Cisplatin, NSCLC, The US, EU5 and Japan, Estimated Sales ($m), 20022020 19
Table 5: Cisplatin, NSCLC, The US, Estimated Sales ($m), 20022020 20
Table 6: Cisplatin, NSCLC, The UK, Estimated Sales ($m), 20022020 21
Table 7: Cisplatin, NSCLC, France, Estimated Sales ($m), 20022020 22
Table 8: Cisplatin, NSCLC, Germany, Estimated Sales ($m), 20022020 23
Table 9: Cisplatin, NSCLC, Italy, Estimated Sales ($m), 20022020 24
Table 10: Cisplatin, NSCLC, Spain, Estimated Sales ($m), 20022020 25
Table 11: Cisplatin, NSCLC, Japan, Estimated Sales ($m), 20022020 26

List of Chart


Figure 1: Percentage Distribution of Top 20 Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Percentage Distribution of Different Types of NSCLC according to Incidence, 2008 6
Figure 4: Percentage Share of Risk Factors in Developed Countries 7
Figure 5: Per Capita Cigarette Consumption, The US, 19762006 7
Figure 6: NSCLC, Global, Market Size Forecast ($bn), 20092020 9
Figure 7: Oncology, Global, Incidence (in million), 20082030 10
Figure 8: NSCLC, Global, Incidence (in million), 20082030 10
Figure 9: Broad Classification of NSCLC 12
Figure 10: Detailed TNM Classification 13
Figure 11: Classification of NSCLC 14
Figure 12: Clinical Trials Results, Cisplatin 15
Figure 13: Drug Model Diagram of Cisplatin 18
Figure 14: Cisplatin NSCLC, The US, EU5 and Japan, Estimated Sales ($m), 20022020 19
Figure 15: Cisplatin, NSCLC, The US, Estimated Sales ($m), 20022020 20
Figure 16: Cisplatin, NSCLC, The UK, Estimated Sales ($m), 20022020 21
Figure 17: Cisplatin, NSCLC, France, Estimated Sales ($m), 20022020 22
Figure 18: Cisplatin, NSCLC, Germany, Estimated Sales ($m), 20022020 23
Figure 19: Cisplatin, NSCLC, Italy, Estimated Sales ($m), 20022020 24
Figure 20: Cisplatin, NSCLC, Spain, Estimated Sales ($m), 20022020 25
Figure 21: Cisplatin, NSCLC, Japan, Estimated Sales ($m), 20022020 26
Figure 22: Distribution of Cisplatin Sales in Major Countries, 2020 27
Figure 23: GlobalData Methodology 28
Figure 24: Drug Model Diagram 30
Figure 25: Patients Approved for the Drug 31

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *